Silence Therapeutics plc

Our mRNAi GOLD™ platform is built to target disease at its source. By delivering siRNAs directly to liver cells and silencing specific disease-related genes, we are advancing a precise approach with the potential to address both common and rare diseases. Learn more about our platform: https://bit.ly/4u8Tt7b #SilenceIsGOLDen

Behind every scientific advancement is the potential to make a difference in someone's life. That's what drives our work at Silence. By harnessing precision-engineeered medicines and bringing together innovation, collaboration, and integrity, we're working to advance new possibilities for patients with limited treatment options. Learn more: https://bit.ly/4gJmiEp

What role could iron regulation play in polycythemia vera (PV)? Our investigational siRNA therapy for people living with PV is designed to silence the TMPRSS6 gene, increasing levels of hepcidin, the body's master iron regulator. This reduces the iron available to the bone marrow, with the aim of limiting red blood cell overproduction. See the science in action in our MOA video: https://bit.ly/4wN5qRW #SilenceIsGOLDen

OncLive featured our phase 1 data presented at EHA 2026, highlighting the potential of our first-in-class siRNA therapy in development for polycythemia vera (PV). Read the article: https://bit.ly/4wwVMTc

Gene silencing works with the body to precisely target and silence disease-associated genes without permanently altering DNA. Our proprietary siRNA platform makes this precise approach possible, unlocking new treatment pathways for patients with limited options. Check out our gene silencing eBook to learn more about this ground-breaking field of research: https://bit.ly/3UGp6GH

We're pleased to share a new publication in the American Journal of Hematology. The study explores the relationship between iron overload, inflammation, and disease progression in a preclinical model of myelodysplastic syndromes (MDS). Researchers found that hepatocyte-targeted silencing of TMPRSS6 reduced iron-driven inflammation, delayed disease progression, and prolonged survival. The findings contribute to our understanding of iron homeostasis in hematologic disease and further support the potential of TMPRSS6 silencing as a therapeutic approach. Congratulations to the authors, including Silence employees Sibylle Dames, Mona Eisermann, Alberto Martinez, and Ute Schaeper, on this important contribution to the field. Read the publication: https://bit.ly/4uYnR4J

Living with polycythemia vera (PV) can make self-care feel more important than ever. Our Mindfulness Coloring Book shares reflections from members of the PV community alongside simple coloring pages created to bring moments of calm, mindfulness, and connection. Download your copy today: https://bit.ly/4daFwAB

Thank you to everyone who connected with us at #EHA2026. We valued the opportunity to share our latest research, exchange ideas, and contribute to discussions focused on improving outcomes for people living with polycythemia vera. Learn more about our work: https://bit.ly/4u67NgK #SilenceIsGOLDen

Why our approach in polycythemia vera (PV)? Our investigational siRNA therapy is designed to target TMPRSS6 with the goal of increasing hepcidin and reducing iron availability for red blood cell production. By targeting iron regulation, we are investigating a potential new approach for people living with PV. Learn more about our investigational siRNA approach in PV: https://bit.ly/4u67NgK

At EHA, we are presenting follow-up and quality-of-life data from our Phase 1 SANRECO study evaluating our siRNA therapy in development for patients living with polycythemia vera (PV). Read more: https://bit.ly/4v7zjvI #SilenceIsGOLDen #EHA2026